drugset / Trial / NCT05649345
TR64 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a open-label, dose escalation, accelerated titration combined 3+3 design, phase I study, to evaluate the safety and tolerability, and to determine the RP2D of TR64 when administered qd in patients with advanced solid tumors. Up to 6 cohorts of 1-6 or 3-6 patients each will be treated in the study.
Timeline
- Start
- 2023-01-12
- Primary completion
- 2026-08-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TR64 | Unknown | 25 mg | Oral |
| Subject | TR64 | Unknown | 400 mg | Oral |
Indications
No indication recorded.